A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

February 24, 2009

Primary Completion Date

March 6, 2017

Study Completion Date

March 6, 2017

Conditions
Heart Transplantation
Interventions
DRUG

Everolimus (EVR)

Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)

DRUG

cyclosporine A (CyA)

10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only

DRUG

tacrolimus (TAC)

0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only

DRUG

Enteric coated mycophenolate sodium (EC-MPS)

180 mg or 360 mg tablet dosed 1440-2280 mg per day

DRUG

mycophenolate mofetil (MMF)

250 mg or 500 mg tablets with a dose of 1500-3000 mg per day

DRUG

Corticosteroids

according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent

Trial Locations (9)

13353

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

30625

Novartis Investigative Site, Hanover

32545

Novartis Investigative Site, Bad Oeynhausen

48149

Novartis Investigative Site, Münster

69120

Novartis Investigative Site, Heidelberg

81377

Novartis Investigative Site, München

93053

Novartis Investigative Site, Regensburg

04289

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY